Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16897910 | 0.81 | NOTUM (0.48) | NOTUMTSHRL3MBTL1RAB9AKCNH2 | |
| SCHEMBL16897931 | 0.78 | KMT2A (0.52) | ALDH1A1TSHRL3MBTL1DRD2DRD3 | |
| SCHEMBL12123607 | 0.76 | SIGMAR1 (0.54) | ALDH1A1NOTUMTSHRL3MBTL1RAB9A | |
| SCHEMBL15601773 | 0.74 | ALDH1A1 (0.52) | ALDH1A1NOTUMKMT2AMEN1MAPK1 | |
| SCHEMBL25937249 | 0.72 | NOTUM (0.61) | NOTUMTSHRL3MBTL1RAB9ASLC6A4 | |
| Hydrochloric Acid SCHEMBL25430303 | 0.71 | NOTUM (0.59) | NOTUMTSHRL3MBTL1RAB9ASLC6A4 | |
| SCHEMBL10837613 | 0.71 | NOTUM (0.59) | NOTUMTSHRL3MBTL1RAB9ACYP3A4 | |
| SCHEMBL2997057 | 0.71 | NOTUM (0.65) | NOTUMTSHRL3MBTL1RAB9AHTR3E | |
| SCHEMBL30452280 | 0.71 | NOTUM (0.65) | NOTUMTSHRL3MBTL1RAB9AHTR3E | |
| SCHEMBL17156567 | 0.69 | CYP3A4 (0.46) | TSHRDRD3KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-10087151-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3091984-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | ALDH1A1 263/4885NOTUM 3808/4885TSHR 2505/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | ALDH1A1 367/4885NOTUM 2588/4885TSHR 3319/4885 |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | ALDH1A1 263/4885NOTUM 3808/4885TSHR 2505/4885 |
| US-10087151-B2 | Substituted benzoxazine and related compounds | CYP4B1, XDH, UGT2B7 | ALDH1A1 263/4885NOTUM 3808/4885TSHR 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.